Recombinant Human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag)

概述

产品介绍

Cat No.

库存：现货

Size

点击咨询在线客服

产品介绍

内毒素

< 1.0 EU per μg protein as determined by the LAL method.

生物活性

1.Flow cytometric analysis of anti-BCMA CAR expression. 5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:125 dilution of PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and negative control protein. Non-transduced 293 cells were used as a control (left). PE signal was used to evaluate the binding activity (QC tested).
2.Binding activity of PE-conjugated BCMA protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
3.Flow cytometric analysis of anti-BCMA CAR expression. HEK293 cells were lentivirally transduced with anti-BCMA CAR. Non-transduced HEK293 cells were used as a control (shown on the left). 2 μL (1 test) of site-specifically PE-conjugated human BCMA protein from two vendors (competitor A and SINO) was used. The results demonstrated that SINO’s 10620-H86H-SP has a much higher fluorescence intensity than that of the competitor (Routinely tested).
4.Flow cytometric analysis using PE conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with PE-conjugated human BCMA protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP). Non-transduced 293 cells were used as a control (Black Histogram). The protein exhibited stable performance after multiple freeze-thaw cycles (5, 10 cycles)

蛋白构建

A DNA sequence encoding the extracellular domain (Met1-Ala54) of human TNFRSF17 (NP_001183.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation = 495-566 nm, Emission Max.= 575 nm).

表达宿主

HEK293 Cells

种属

Human

预测 N 端

Met 1

分子量

The protein has a predicted molecular mass of 11.8 kDa.

缓冲液

This product is Lyophilized from sterile PBS, pH 7.4, with 5 %-8 % trehalose and 0.2% BSA.
Please contact us for any concerns or special requirements.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

运输方式

It is provided as lyophilized powder which are shipped at ambient temperature.

稳定性 & 储存条件

Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 6 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.

复溶

To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA.

Flow cytometric analysis of anti-BCMA CAR expression. 5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:125 dilution of PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and negative control protein. Non-transduced 293 cells were used as a control (left). PE signal was used to evaluate the binding activity (QC tested).

Binding activity of PE-conjugated BCMA protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and PE-conjugated human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

Flow cytometric analysis of anti-BCMA CAR expression. HEK293 cells were lentivirally transduced with anti-BCMA CAR. Non-transduced HEK293 cells were used as a control (shown on the left). 2 μL (1 test) of site-specifically PE-conjugated human BCMA protein from two vendors (competitor A and SINO) was used. The results demonstrated that SINO’s 10620-H86H-SP has a much higher fluorescence intensity than that of the competitor (Routinely tested).

1.Flow cytometric analysis using PE conjugated BCMA protein. 5e5 of anti-BCMA CAR-293 cells were stained with PE-conjugated human BCMA protein (Site-Specific PE Conjugation, ECD, His Tag, Cat. No. 10620-H86H-SP). Non-transduced 293 cells were used as a control (Black Histogram). The protein exhibited stable performance after multiple freeze-thaw cycles (5, 10 cycles)

Recombinant Human BCMA Protein (Site-Specific PE Conjugation, ECD, His Tag): 别称

BCM Protein, Human; BCMA Protein, Human; CD269 Protein, Human; TNFRSF13A Protein, Human

BCMA 背景信息

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

全称

tumor necrosis factor receptor superfamily member 17

参考文献

Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94.
O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8.
Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.